The U.S. Food and Drug Administration (FDA) has granted treprostinil orphan drug designation for the treatment of idiopathic pulmonary…
Articles by Marisa Wexler, MS
The global COVID-19 pandemic has had a negative local impact on healthcare for most people in the U.K. with…
Newly developed therapies may hold promise for the treatment of pulmonary fibrosis, as described in two studies. The therapies,…
Galapagos and OncoArendi Therapeutics have entered into an exclusive agreement for the global development and commercialization…
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of…
A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like…
Newly raised equity financing will advance Galecto‘s clinical pipeline, which includes GB0139, a potential inhalation treatment for idiopathic…
In recognition of September being Pulmonary Fibrosis Awareness Month, the Pulmonary Fibrosis Foundation (PFF) is working to raise awareness…
In the U.S., idiopathic pulmonary fibrosis (IPF) mortality rates decreased from 2004 to 2017, a new study shows. The…
AbbVie will assume development of Morphic Therapeutic‘s alpha v beta 6 (αvβ6) integrin inhibitors as potential treatments for…